Table 1 Baseline clinical and angiographic characteristics of study population
Characteristics | Total (n = 2312) | ISR (n = 372) | Non-ISR (n = 1940) | P values |
|---|---|---|---|---|
Age, years | 56.21 ± 9.65 | 55.31 ± 9.67 | 56.38 ± 9.63 | 0.050 |
Male, n (%) | 1652 (71.5) | 272 (73.1) | 1380 (71.1) | 0.438 |
BMI, kg/m2 | 26.45 ± 3.04 | 26.52 ± 2.99 | 26.43 ± 3.05 | 0.618 |
SBP, mmHg | 131.45 ± 17.65 | 130.40 ± 15.92 | 131.65 ± 17.96 | 0.209 |
DBP, mmHg | 77.97 ± 10.23 | 77.63 ± 10.97 | 78.04 ± 10.09 | 0.509 |
Smoking, n (%) | 928 (40.1) | 116 (31.2) | 812 (41.9) | < 0.001 |
Drinking, n (%) | 360 (15.6) | 64 (17.2) | 296 (15.3) | 0.343 |
Medical history, n (%) | ||||
Hypertension | 1568 (67.8) | 240 (64.5) | 1328 (68.5) | 0.136 |
Hyperlipidaemia | 1140 (49.3) | 228 (61.3) | 912 (47.0) | < 0.001 |
History of MI | 204 (8.8) | 24 (6.5) | 180 (9.3) | 0.078 |
History of stroke | 180 (7.8) | 16 (4.3) | 164 (8.5) | 0.006 |
Family history of CAD | 208 (17.6) | 68 (18.3) | 340 (17.5) | 0.727 |
Symptom for CAG | 1354 (58.6) | 234 (62.9) | 1120 (57.7) | 0.064 |
Laboratory results | ||||
TG, mmol/L | 2.22 ± 1.54 | 2.62 ± 2.16 | 2.14 ± 1.37 | < 0.001 |
TC, mmol/L | 4.43 ± 1.07 | 4.81 ± 1.12 | 4.35 ± 1.04 | < 0.001 |
LDL-C, mmol/L | 2.77 ± 0.90 | 2.81 ± 0.87 | 2.77 ± 0.94 | 0.348 |
HDL-C, mmol/L | 1.00 ± 0.26 | 1.04 ± 0.97 | 0.57 ± 0.44 | < 0.001 |
RLP-C, mmol/L | 0.65 ± 0.59 | 0.94 ± 1.00 | 0.59 ± 0.44 | < 0.001 |
FBG, mmol/L | 7.69 ± 2.50 | 7.64 ± 2.20 | 7.71 ± 2.55 | 0.591 |
HbA1c, % | 7.35 ± 1.30 | 7.41 ± 1.21 | 7.34 ± 1.31 | 0.283 |
hs-CRP, mg/L | 4.72 ± 6.98 | 4.60 ± 5.93 | 4.75 ± 7.16 | 0.662 |
Creatinine, μmol/L | 77.35 ± 19.15 | 77.10 ± 18.23 | 77.40 ± 19.33 | 0.782 |
GFR, ml/min | 113.70 ± 316.21 | 184.46 ± 782.91 | 100.13 ± 27.43 | 0.038 |
UA, μmol/L | 335.49 ± 107.15 | 332.01 ± 129.22 | 336.16 ± 102.40 | 0.560 |
LVEF, % | 61.83 ± 8.14 | 62.15 ± 7.37 | 61.76 ± 8.28 | 0.363 |
Medical treatment, n (%) | ||||
Statins | 2164 (93.6) | 340 (91.4) | 1824 (94.0) | 0.058 |
Aspirin | 2272 (98.3) | 364 (97.8) | 1908 (98.4) | 0.497 |
β-Blocker | 1776 (76.8) | 284 (76.3) | 1492 (76.9) | 0.814 |
Clopidogrel | 2292 (99.1) | 364 (97.8) | 1928 (99.4) | 0.003 |
Insulin | 556 (24.0) | 76 (20.4) | 480 (24.7) | 0.075 |
ACEI | 700 (30.3) | 92 (24.7) | 608 (31.3) | 0.011 |
ARB | 548 (23.7) | 80 (21.5) | 468 (24.2) | 0.268 |
Number of target vessels | <  0.001 | |||
One, n (%) | 792 (34.3) | 124 (33.3) | 668 (34.4) | Â |
Two, n (%) | 948 (41.0) | 112 (30.1) | 836 (43.1) | Â |
Three, n (%) | 564 (24.4) | 128 (34.4) | 436 (22.5) | Â |
Target vessels | ||||
LM, n (%) | 56 (2.4) | 8 (2.2) | 48 (2.5) | 0.710 |
LAD, n (%) | 1316 (56.9) | 244 (65.6) | 1072 (55.3) | <  0.001 |
LCX, n (%) | 724 (31.1) | 140 (37.6) | 584 (30.1) | 0.004 |
RCA, n (%) | 884 (38.2) | 160 (43.0) | 724 (37.3) | 0.039 |
SYNTAX score | 12.07 ± 6.98 | 14.08 ± 7.55 | 11.68 ± 6.79 | <  0.001 |
Minimal stent diameter, mm | 2.95 ± 0.46 | 2.93 ± 0.41 | 2.95 ± 0.47 | 0.460 |
Stent length, mm | 22.02 ± 6.60 | 22.63 ± 5.82 | 21.90 ± 6.75 | 0.035 |